Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility
2017/11/27 by Nobuyuki Takahashi, Yukinori Take · 28 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Gastroesophageal reflux and treatments #Ion Transport and Channel Regulation #Helicobacter pylori-related gastroenterology studies
paper · pdf · doi:10.1124/jpet.117.244202
Abstract
Tegoprazan [(<i>S</i>)-4-((5,7-difluorochroman-4-yl)oxy)-<i>N</i>,<i>N</i>,2-trimethyl-1<i>H</i>-benzo[d]imidazole-6-carboxamide], a potassium-competitive acid blocker (P-CAB), is a novel potent and highly selective inhibitor of gastric H<sup>+</sup>/K<sup>+</sup>-ATPase. Tegoprazan inhibited porcine, canine, and human H<sup>+</sup>/K<sup>+</sup>-ATPases in vitro with IC<sub>50</sub> values ranging from 0.29 to 0.52 <i>μ</i>M, while that for canine kidney Na<sup>+</sup>/K<sup>+</sup>-ATPase was more than 100 <i>μ</i>M. A kinetic analysis revealed that tegoprazan inhibited H<sup>+</sup>/K<sup>+</sup>-ATPase in a potassium-competitive manner and the binding was reversible. Oral single administrations of tegoprazan ranging from 0.3 to 30 mg/kg in dogs were well absorbed into the blood stream and distributed in gastric tissue/fluid higher than in plasma. Tegoprazan potently inhibited histamine-induced gastric acid secretion in dogs, and a complete inhibition was observed at 1.0 mg/kg starting from 1 hour after administration. Moreover, an oral administration of tegoprazan at 1 and 3 mg/kg reversed the pentagastrin-induced acidified gastric pH to the neutral range. Interestingly, 3 mg/kg tegoprazan immediately evoked a gastric phase III contraction of the migrating motor complex in pentagastrin-treated dogs and similar effects was observed with the other P-CAB, vonoprazan. Tegoprazan is the novel P-CAB that may provide a new option for the therapy of gastric acid–related and motility-impaired diseases.
Cited by
- Renal Outcomes With Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in CKD
- Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ‐12420), a novel potassium‐competitive acid blocker, in healthy male subjects
- Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
- Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. [europepmc]
- Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. [europepmc]
- Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. [europepmc]
- Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. [europepmc]
- The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. [europepmc]
- Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans. [europepmc]
- Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. [europepmc]
- Prediction of Drug-Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation. [europepmc]
- 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. [europepmc]
- Model-Based Prediction of Acid Suppression and Proposal of a New Dosing Regimen of Fexuprazan in Humans. [europepmc]
- Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial. [europepmc]
- Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. [europepmc]
- Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study. [europepmc]
- Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial. [europepmc]
- Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study. [europepmc]
- Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016-2020): A Recapitulation of Chirality. [europepmc]
- Neuroendocrine mechanism of gastric acid secretion: Historical perspectives and recent developments in physiology and pharmacology. [europepmc]
- Anti-Inflammatory Effects of Tegoprazan in Lipopolysaccharide-Stimulated Bone-Marrow-Derived Macrophages. [europepmc]
- Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study. [europepmc]
- Efficacy of Tegoprazan in Patients With Functional Dyspepsia: A Prospective, Multicenter, Single-arm Study. [europepmc]
- Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis. [europepmc]
- Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments. [europepmc]
- Efficacy and safety of tegoprazan (LXI-15028) vs . esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase Ⅲ trial. [europepmc]
- Efficacy and Safety of Fexuprazan Versus Esomeprazole for Gastroesophageal Reflux Disease-Related Chronic Cough: A Randomized, Double-Blind, Active-Controlled Exploratory Trial. [europepmc]
- Tegoprazan as First- and Second-Line Therapy for Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. [europepmc]
Related